English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The inhibition activities of sulfonamide and sulfamate derivatives for human carbonic anhydrases have been quantitatively analyzed using DRAGON descriptors. QSAR models have been obtained through combinatorial protocol-multiple linear regression (CP-MLR) computational procedure. For the hCA I inhibition activity, a higher value of information content index of the 1-order neighborhood symmetry (IC1) and a lower value of the Moran autocorrelations, MATS2v and MATS1p, along with a lower number of sulfur atoms in a molecular structure (nRSR) is beneficial to the activity. A higher number of 5-membered rings (nR05), a bigger distance between nitrogen and sulfur T(N..S), and a higher value of van der Waals volume weighted descriptor (GATS6v), are helpful to improve the hCA II inhibition activity. For the inhibition of hpCA, a lower value of the descriptors Jhetv and PW5, and higher values of the eigenvalue sum from Z weighted distance matrix, SEigZ, the Moran autocorrelation of lag 8 weighted by atomic van der Waals volumes, MATS8v and the Moran autocorrelation of lag 4 weighted by atomic Sanderson electronegativities, MATS4e are favorable. The derived significant models in such descriptors may further be used to synthesize new potential compounds and to decipher the mode of their actions at molecular level.

CP-MLR directed QSAR study of carbonic anhydrase inhibitors: sulfonamide and sulfamate inhibitors